目的 分析湖北省第三人民醫(yī)院住院患者抗新型冠狀病毒肺炎（COVID-19）藥物的使用情況。方法 收集2020年1月24日-2020年2月19日湖北省第三人民醫(yī)院已出院的110例COVID-19確診患者的臨床資料，采用世界衛(wèi)生組織推薦的限定日劑量（DDD）法對(duì)藥物總金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）和排序比（B/A）進(jìn)行統(tǒng)計(jì)分析。結(jié)果 藥物總金額排序居前3位的藥物類別分別為免疫增強(qiáng)藥、喹諾酮類和碳青霉烯類，排序居前3位的藥品依次為人免疫球蛋白、莫西沙星和美羅培南。DDDs排序居前3位的藥物類別分別為免疫增強(qiáng)藥、糖皮質(zhì)激素類及質(zhì)子泵抑制藥，排序居前3位的藥品依次為人免疫球蛋白、甲潑尼龍和莫西沙星。DDC較高的有藥品有美羅培南、莫西沙星和哌拉西林鈉/舒巴坦鈉；B/A較高的有甲潑尼龍、蒙脫石散、奧司他韋，B/A較低的有美羅培南、頭孢哌酮鈉舒巴坦鈉和頭孢哌酮鈉/他唑巴坦鈉。結(jié)論 湖北省第三人民醫(yī)院COVID-19藥物的使用基本合理，但仍然存在不足，需進(jìn)一步加強(qiáng)管理，其中抗菌藥物的同步性較差，臨床應(yīng)用合理性有待考證。

Objective To analyze the utilization of anti-new coronavirus disease 2019 (COVID-19) drugs of inpatients in Hubei No. 3 People's Hospital. Methods The clinical data of 110 COVID-19 patients diagnosed in the Third People's Hospital of Hubei Province from January 24, 2020 to February 19, 2020 were collected and analyzed. Total drug amounts, defined daily dose system (DDDs), defined daily cost (DDC), and sequencing ratio (B/A) were analyzed by defined daily dose (DDD) method recommended by the world health organization (WHO). Results The top three drug categories in terms of total drug amounts were immune enhancers, quinolones, and carbapenems. The drugs with top three total drug amounts were human immunoglobulin, moxifloxacin, and meropenem. The drug categories with top three DDDs were immune enhancers, glucocorticoids, and proton pump inhibitors. The top three drugs ranked by DDDs were human immunoglobulin, methylprednisolone, and moxifloxacin, respectively. DDC of meropenem, moxifloxacin, and piperacillin/sulbactam were higher. Methyl prednisolone, montmorillonite powder, and oseltamivir had higher B/A, and B/A of meropenem, cefoperazone/sulbactam, and cefoperazone/tazobartan were lower. Conclusion The utilization of anti-COVID-19 drugs in the Third People's Hospital of Hubei Province is rational on the whole, but there are still some problems, which needs further efforts to strengthen the management and intervention. The synchrony of antibiotics is poor, and their rationality of clinical application remains to be proved.

R978.1

湖北省衛(wèi)生健康委員會(huì)科研項(xiàng)目（WJ2019F170）；武漢市中青年醫(yī)學(xué)骨干人才項(xiàng)目（武衛(wèi)生計(jì)生[2017]51號(hào)）